|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-55.43/-2.29
|
企業價值
492.18M
|
資產負債 |
每股賬面淨值
0.03
|
現金流量 |
現金流量率
--
|
損益表 |
收益
26.00M
|
每股收益
0.32
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/12/23 22:12 EST
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. It leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. Unlike DNA, mRNA degrades naturally over time without integrating into the cell's genetic material. |